Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?
- 16 March 2021
- journal article
- letter
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1427-1428
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitorsEuropean Journal of Clinical Pharmacology, 2020
- Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized doseBritish Journal of Clinical Pharmacology, 2019
- Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their developmentCardio-Oncology, 2017
- Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patientsBest Practice & Research Clinical Endocrinology & Metabolism, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingClinical Pharmacokinetics, 2017
- Therapeutic Drug Monitoring to Individualize the Dosing of PazopanibTherapeutic Drug Monitoring, 2015
- Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patientsThe Pharmacogenomics Journal, 2015
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinomaBritish Journal of Cancer, 2014
- Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trialsInternational Journal of Cancer, 2014